In the Makonde language, “Chikungunya” translates to “that which bends up”, descriptive of the twisted posture of those infected secondary to intense joint and muscle pain experienced during the acute phase of the disease.  

A comprehensive review of psoriatic arthritis (PsA) was published this week in the NEJM, authored by leaders in the field, Drs. Ritchlin, Colbert and Gladman.

High points from their review inlcuded:

A a randomized trial published in Annals of Internal Medicine shows that intradiscal glucocorticoid injection has limited (1 month) efficacy in treating low back pain (LBP) associated with active discopathy, yet decreased over time.

Clinical Rheumatology reports that the repeated intravenous administration of gadolinium-based contrast agents (GBCAs), although clinically useful, may be associated with rare toxicity and the uncertain clinical effects of accumulation. 

SLE-related hepatitis (“lupus hepatitis”) and “lupoid hepatitis” are 2 different diseases. The term "lupoid hepatitis", now known as autoimmune hepatitis (AIH), was first coined in 1959. AIH was initially called “lupoid hepatitis” by MacKay.  A review by Adiga and Nugent reviews, defines and distinguishes between lupus-related hepatitis and lupoid hepatitis.

A French population based study of ankylosing spondylitis (AS) was report in the Journal of Rheumatology.

They analyzed the death certificates and cause of death in 2940 AS patients over 3 different decades (1969-78; 1979-99; 2000-2009).

Calabrese and Velcheti have reviewed the current understanding that underlies a new drug-induced rheumatic disease - checkpoint inhibitor arthritis and autoimmune disease.

Dr. Sharad Lakhanpal, MBBS, MD, President of the American College of Rheumatology (ACR) has issued a press release condeming the insufficiencies of the newly proposed American Health Care Act (AHCA).

In January 2017, the Food and Drug Administration (FDA) released its draft guidance on the issue of interchangeability between biosimilars and originator biologic drugs. The window for your input will close on May 18, 2017. RheumNow encourages you to participate in this exercise and express your opinion.

The March 2017 issue of the ACP Internist has reviewed the ubiquitous practice of medication adherence. 

CNN has reported that changes in immigration policies is but one of many factors that may add to an existing doctor shortage. This and other events now begs the the question, why the federal government doesn't train more doctors in the US?

The ACGME has revised its traing guidelines such that, starting July 1st, new interns are allowed to work shifts lasting as long as 24 hours, and as much as 28 hours according to a recent New York Times article.  

Most physicians believe they understand and can manage gout. Yet, the number of gout patients has risen at an alarming rate and the introduction of 4 new drugs has done little to close the education gap and improve the care and outcomes of gout patients. Misuse, misunderstandings and missed opportunities abound in the wide world of gout.

Treat-to-target (T2T) works when they are pragmatic and conform well to daily practice.  

Gout is an ideal therapeutic area where T2T could be and should be applied.

Dr. Jack Cush reviews news and highlights from the past week on RheumNow.com.  Sign up at RheumNow.com to received daily or weekly news, blogs and tweets on all things rheumatology

The current JAMA has a perspective piece on the role of the oral microbiome in the pathogenesis and references a recent article by Konig et al on "Aggregatibacter actinomycetemcomitans–induced hypercitrullination links periodontal infection to autoimmunity in rheumatoid arthritis (RA)." (Citation

In the United States, doctor-diagnosed arthritis is a common and widespread chronic condition (1,2). Arthritis is a leading cause of disability (3) and is projected to affect 78.4 million adults by 2040.

The current issue of the Journal of the American College of Cardiology reports on the relative risk of heart failure (HF) in rheumatoid arthritis (RA) and its relation to ischemic heart disease (IHD).

The February 2017 RheumNow “Live Vote” surveyed US and non-US rheumatologists about their beliefs and practices regarding folic acid and methotrexate (MTX) use. A total of 495 responses were tabulated in 2 weeks. Here are the results, and comments from Dr. Kremer on his preferred answers to these questions.

Arthritis Care & Research has reported the results of a study that analyzed the perceptions and attitudes of men afflicted with rheumatoid arthritis (RA).  The results are drawn from a series of focus groups involving 22 men with RA.